<DOC>
	<DOCNO>NCT02457221</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety Tacrolimus capsule induction remission patient lupus nephritis , compare efficacy safety Cyclophosphamide injection .</brief_summary>
	<brief_title>A Study Compare Efficacy Safety Tacrolimus Capsules Cyclophosphamide Injection Treatment Lupus Nephritis</brief_title>
	<detailed_description>This randomize , open , 1:1 parallel control , multi-center , non-inferiority clinical study .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>18.5≤Body Mass Index ( BMI ) &lt; 27 ; Diagnosed systemic lupus erythematosus ( base American Rheumatism Association Diagnostic Criteria 1997 ) Diagnosed III , IV , V , III + V , IV + V lupus nephritis ( accord LN classification International Society Nephrology Renal Pathology Society ( ISN/RPS ) 2003 ) within 24 week enrollment renal biopsy ; 24hour urine protein ≥ 1.5g , Scr &lt; 260umol/L ( 3mg/dL ) Class II VI lupus nephritis renal biopsy chronic index ( CI ) &gt; 3 TMA ; Received immunosuppressant ( mycophenolate mofetil ( MMF ) , cyclosporine , methotrexate , mechlorethamine , chlorambucil , tripterygium preparation , leflunomide etc . ) treatment duration one week within 30 day prior enrollment ; Received tacrolimus ( except topical use ) cyclophosphamide treatment within 30 day prior enrollment ; Received course methylprednisolone ( MP ) pulse therapy gamma globulin treatment plasma exchange within 30 day prior enrollment ; Patients history allergy tacrolimus , cyclophosphamide methylprednisolone ; Pregnancy , lactation patient unwilling take contraceptive measure ; Patients estimate maintenance dialysis eight week ; dialysis two week prior enter observation ; Patients receive kidney transplantation plan kidney transplantation recently ; Serum creatinine ( Scr ) ≥260umol/L ( 3mg/dL ) creatinine clearance rate ( Ccr ) &lt; 30ml/ ( min.1.73m2 ) ; accord CockcroftGault formula : Ccr ( ml/sec ) = [ ( 140 age ) × Weight ( kg ) ] × K / [ 72×Scr ( umol/L ) ×0.6786 ] , Female K = 0.85 , Male K = 1.0 ; Patients suffer liver dysfunction ( aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 3 time upper limit normal lab value ) bilirubin 3 time upper limit normal lab value ; Patients diagnose diabetes ; History gastrointestinal bleeding pancreatitis within 3 month ; Uncontrollable hyperkalemia dietary therapy reduction potassium treatment ( exceed upper limit normal lab value ) ; Patients suffer lupus pneumonia lung injury ; Patients anemia ( hemoglobin &lt; 7g/dl ) bone marrow suppression ( WBC &lt; 3.0×109/L , and/or neutrophil &lt; 1.5×109/L , and/or platelet &lt; 50×109/L ) secondary systemic lupus erythematosus ; With congenital heart disease , arrhythmia , heart failure severe cardiovascular disease ; With refractory hypertension ( define blood pressure still exceed 180/110 mmHg despite take three different type antihypertensive drug [ one diuretic ] simultaneously ) ; Patients recurrent tumor within 5 year ; Severe infection require intravenous antibiotic within 2 week prior enrollment ; Patients infection hepatitis B virus hepatitis C virus ; patient active tuberculosis ; patient severe immunodeficiency disease ( include active cytomegalovirus infection ( positive CMV IgM antibody ) , human immunodeficiency virus ( HIV ) infection , etc . ) ; Patients lupus encephalopathy lifethreatening complication systemic lupus erythematosus ; Patients participate clinical trial within three month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Prograf</keyword>
	<keyword>lupus nephritis</keyword>
</DOC>